FY19/20 started on a positive note with double-digit sales growth for both Microsurgery and Ophthalmic Devices segments, backed by robust demand in the US and Asia-Pacific. Operating profit was also up in double-digits, though the benefits of the favourable product mix were partly offset by higher R&D investments. While FY19/20 EBIT margin guidance was reiterated, management has turned slightly cautious with its sales growth outlook. The outbreak of the corona virus also poses a temporary
10 Feb 2020
Despite a strong Q1, management turns slightly cautious with its full-year sales outlook
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Despite a strong Q1, management turns slightly cautious with its full-year sales outlook
Carl Zeiss Meditec AG (AFX:WBO) | 0 0 1.8% | Mkt Cap: 4,494m
- Published:
10 Feb 2020 -
Author:
Sumit Sayal -
Pages:
3
FY19/20 started on a positive note with double-digit sales growth for both Microsurgery and Ophthalmic Devices segments, backed by robust demand in the US and Asia-Pacific. Operating profit was also up in double-digits, though the benefits of the favourable product mix were partly offset by higher R&D investments. While FY19/20 EBIT margin guidance was reiterated, management has turned slightly cautious with its sales growth outlook. The outbreak of the corona virus also poses a temporary